Aktionsplan Context Therapeutics Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen Context Therapeutics Inc.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.| IPO date | 2021-10-20 |
|---|---|
| ISIN | US21077P1084 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.contexttherapeutics.com |
| Цена ао | 1.27 |
| Preisänderung pro Tag: | -3.51% (1.14) |
|---|---|
| Preisänderung pro Woche: | +7.84% (1.02) |
| Preisänderung pro Monat: | -26.67% (1.5) |
| Preisänderung über 3 Monate: | -40.86% (1.86) |
| Preisänderung über sechs Monate: | -40.22% (1.84) |
| Preisänderung pro Jahr: | -2.65% (1.13) |
| Preisänderung über 3 Jahre: | -60.99% (2.82) |
| Preisänderung über 5 Jahre: | 0% (1.1) |
| Preisänderung über 10 Jahre: | 0% (1.1) |
| Preisänderung seit Jahresbeginn: | -49.31% (2.17) |
|
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institutionen | Volumen | Aktie, % |
|---|---|---|
| Opaleye Management Inc. | 975000 | 6.11 |
| Ally Bridge Group (NY) LLC | 725951 | 4.55 |
| Vanguard Group Inc | 596012 | 3.73 |
| Affinity Asset Advisors, LLC | 328817 | 2.06 |
| UBS OConnor LLC | 296675 | 1.86 |
| HighTower Advisors, LLC | 125852 | 0.79 |
| Bridgeway Capital Management, Inc. | 105809 | 0.66 |
| Mill Creek Capital Advisors, LLC | 104631 | 0.66 |
| Geode Capital Management, LLC | 97240 | 0.61 |
| Northern Trust Corporation | 37219 | 0.23 |
| Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
|---|---|---|---|
| Mr. Martin A. Lehr | Co-Founder, President, CEO & Director | 674.08k | 1984 (41 Jahr) |
| Ms. Jennifer Minai-Azary | CFO & Treasurer | 504.14k | 1978 (47 Jahre) |
| Mr. Alex C. Levit Esq. | Chief Legal Officer & Corporate Secretary | 483.83k | 1979 (46 Jahre) |
| Mr. Christopher Beck M.B.A. | Senior Vice President of Operations | N/A | |
| Dr. Claudio Dansky Ullmann M.D. | Chief Medical Officer |
Adresse: United States, Philadelphia. PA, 2001 Market Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.contexttherapeutics.com
Webseite: https://www.contexttherapeutics.com
